文献速递淋巴瘤白血病

CD19靶向嵌合抗原受体T细胞治疗继发性神经淋巴瘤病的毒性反应与结局

Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis.
PubMed 文献 · Am J Hematol · 2024-10-23

该回顾性研究在麻省总医院6年间识别11例接受CD19-CAR T细胞治疗的神经淋巴瘤病患者,低级别细胞因子释放综合征见于8/11(73%),低级别免疫细胞相关神经毒性综合征见于5/11(45%),高级别见于1/11(9%),7/11(64%)有效,完全缓解3例(27%),中位无进展生存期4个月。

要点

  • 低级别细胞因子释放综合征见于8/11(73%),低级别免疫细胞相关神经毒性综合征见于5/11(45%)。
  • 输注时C反应蛋白水平可预测免疫细胞相关神经毒性综合征(曲线下面积0.96,p=0.01)。
  • 7/11(64%)患者有效,完全缓解3例(27%),中位无进展生存期4个月。

核心结论

  • CD19-CAR T细胞治疗在复发性神经淋巴瘤病中耐受良好并显示出有前景的疗效,该病为难以治疗且存在未满足医疗需求的疾病。
  • 研究结果提示CD19-CAR可能充分穿透血神经屏障。
  • 毒性反应和结局总体与中枢神经系统淋巴瘤的CAR-T细胞治疗相似。

研究设计与样本

  • 回顾性研究,在麻省总医院6年期间识别接受CD19-CAR T细胞治疗的神经淋巴瘤病患者。
  • 共识别11例神经淋巴瘤病患者,接受CD19-CAR T细胞前周围神经系统导向治疗的中位线数为2线(范围1-3)。
  • 毒性按ASTCT分类分级,记录管理和缓解率。

主要发现

  • 神经淋巴瘤病定位:神经根8/11(73%)、神经丛5/11(45%)、周围神经4/11(36%)、脑神经5/11(45%)。
  • 低级别细胞因子释放综合征见于8/11(73%;1级N=7;2级N=1)。
  • 低级别免疫细胞相关神经毒性综合征见于5/11(45%;1级N=4;2级N=1),高级别见于1/11(9%;4级)。
  • 输注时C反应蛋白水平可预测免疫细胞相关神经毒性综合征(曲线下面积0.96,p=0.01)。
  • 7/11(64%)患者对CD19-CAR T细胞有应答,完全缓解3例(27%),其中2例在CD19-CAR输注后9个月和46个月维持持续完全缓解;中位无进展生存期4个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lymphomatous infiltration of the peripheral nervous system (PNS), termed neurolymphomatosis, represents a distinct extranodal non-Hodgkin lymphoma variant with dismal outcome. CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has emerged as a safe and effective treatment for B-cell lymphomas. We aimed to assess toxicity and efficacy of CD19-CAR T-cells in neurolymphomatosis. Neurolymphomatosis patients treated with CD19 CAR T-cells were retrospectively identified at Massachusetts General Hospital over a six-year period. Toxicities were graded according to the ASTCT classification, management, and response rates were recorded. Eleven neurolymphomatosis patients were identified with a median of 2 lines of PNS-directed treatments (range: 1-3) prior to receiving CD19-CAR T-cells. Neurolymphomatosis localized to the nerve roots (8/11, 73%), plexus (5/11, 45%), peripheral (4/11, 36%) and cranial nerves (5/11, 45%). Low grade cytokine release syndrome (CRS) was detected in 8/11 (73%; grade 1: N = 7; grade 2: N = 1) cases. Low- and high-grade immune cell-associated neurotoxicity syndrome (ICANS) were recorded in 5/11 (45%; grade 1: N = 4; grade 2: N = 1) and 1/11 (9%; grade 4) patients, respectively. CRP levels at infusion were predictive of ICANS (area under the curve: 0.96, p = 0.01). Seven of eleven neurolymphomatosis patients (64%) responded to CD19-CAR T-cells. Complete remissions (CR) were achieved in three cases (27%), with 2 patients in sustained CR nine and 46 months after CD19-CAR infusion. Median progression-free survival (PFS) was 4 months. Collectively, CD19-CAR T-cell treatment was well tolerated and showed promising efficacy in recurrent neurolymphomatosis, a difficult to treat condition with unmet medical need. Findings suggest that CD19-CAR may sufficiently penetrate the blood-nerve barrier. Toxicity and outcomes were overall similar to CAR-T cell therapy in CNS lymphoma.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kaulen LD, Karschnia P, Doubrovinskaia S, et al. Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis. Am J Hematol. 2024. PMID: 39440883. doi:10.1002/ajh.27505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。